Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer

Published:2009-05 Issue:4 Volume:36 Page:363-369
ISSN:0969-8051
Container-title:Nuclear Medicine and Biology
language:en
Short-container-title:Nuclear Medicine and Biology

Author:

Rasaneh Samira,Rajabi Hossein,Babaei Mohammad Hossein,Daha Fariba Johari,Salouti Mojtaba

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Molecular Medicine

Reference21 articles.

1. HER-2-Positive metastatic breast cancer: trastuzumab and beyond;Metro;Expert Opin Pharmacother,2008

2. Molecular targets for breast cancer therapy and prevention;Bange;Nat Med,2001

3. Overview of tyrosine kinase inhibitors in clinical breast cancer;Agrawal;Endocr Relat Cancer,2005

4. HER-2-Targeted therapy — lessons learned and future directions;Nahta;Clin Cancer Res,2003

5. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4;Albanell;Adv Exp Med Biol,2003

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Vitro Assessment of 177Lu-Labeled Trastuzumab-Targeted Mesoporous Carbon@Silica Nanostructure for the Treatment of HER2-Positive Breast Cancer;Pharmaceuticals;2024-06-05

2. TMACH-1,2-HOPO, a versatile tripodal metal chelator: complexation, solution thermodynamics, spectroscopic and DFT studies;Journal of Inclusion Phenomena and Macrocyclic Chemistry;2024-02-16

3. Formulation of patient dose of [¹⁷⁷Lu]Lu‐Trastuzumab using in‐house developed freeze‐dried kit: A path forward for clinical translation;Journal of Labelled Compounds and Radiopharmaceuticals;2024-02-11

4. In Vitro Assessment of 177Lu-labeled Trastuzumab-Targeted Mesoporous Carbon@Silica Nanostructure for the treatment of HER2-Positive Breast Cancer;2023-11-08

5. Development of Novel Trifunctional Chelating Agents That Enhance Tumor Retention of Radioimmunoconjugates;Journal of Medicinal Chemistry;2023-09-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3